MSB 2.03% $1.45 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-204

  1. 146 Posts.
    lightbulb Created with Sketch. 16
    @stockrock - many thanks for your fantastic posts.

    I have been badly burned by the SP impact of the FDA CRL yesterday

    How sure are you in saying the CRL is a Class 2? The Mesoblast announcement doesn’t say FDA requested a pre or post approval additional clinical trial

    Thanks in advance
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.